Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Medical Devices

Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, upper extremities, and trauma and CMFT products; sports medicine products for the repair of soft tissue injuries, used in the knee and shoulder; and craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open-heart surgery, trauma, or for deformities of the chest. It offers technology and data, bone cement, and surgical products; and a suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, hospitals, healthcare institutions, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. It also offers ROSA Robot, which utilizes robotic technologies to assist a surgeon with implant positioning in total knee arthroplasty or partial knee arthroplasty; and the ZBEdge Platform connects robotic and digital technologies together to collect data before, during and after surgery, that can deliver insights to surgeons to assist in making informed decisions on patient care. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.

Revenue projections:

Revenue projections for ZBH
Revenue projections for ZBH

The projected decline in ZBH's revenues compared to last year is expected to make investors cautious. A drop in revenue often has a direct negative effect on the company's bottom line, signaling potential challenges that could undermine investor confidence and reduce overall profitability.

Financial Ratios:

currentRatio 1.362000
forwardPE 12.741817
debtToEquity 53.611000
earningsGrowth 0.597000
revenueGrowth 0.040000
grossMargins 0.718950
operatingMargins 0.179970
trailingEps 5.240000
forwardEps 8.600000

A current ratio of 1.362 for ZBH implies that the company has ample liquidity to meet its short-term debts. ZBH's cash reserves and current assets should easily cover these obligations, highlighting its financial stability and ability to manage short-term liabilities.
Zimmer Biomet Holdings, Inc.'s Forward PE is in an attractive range, meaning its stock price aligns well with earnings and isn't inflated. This creates room for growth, making it a solid investment opportunity for those looking to benefit from potential price appreciation.
Zimmer Biomet Holdings, Inc.'s forward EPS exceeding its trailing EPS reflects expectations of increased profitability for the current year. This suggests that the company is projected to achieve higher earnings than in the previous financial year, signaling positive growth and improved financial health.

Price projections:

Price projections for ZBH
Price projections for ZBH

Zimmer Biomet Holdings, Inc.'s price has consistently hovered around the lower end of analysts' projections. This pattern may reflect concerns regarding the company's ability to achieve its anticipated growth.

Recommendation changes over time:

Recommendations trend for ZBH
Recommendations trend for ZBH


ZBH has been receiving a buy bias from analysts, indicating confidence in its investment potential. This could drive more investors to view ZBH as a reliable choice for their money, offering a promising avenue for future growth and financial gains.